Sun, Jan 25, 2015, 2:05 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Boston Scientific Corporation Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • invest91765 invest91765 Jan 23, 2005 1:49 PM Flag

    New Article

    I respectfully and strongly disagree! The study has enrolled over 1300 patients, and the study itself does not over stratify. Yes they designed a study that 32% diabetic, it will have difficult lesions, but that is not over stratification. Now many people are going to poor over certain subsets, one being insulin dependent diabetics. A lot of post analysis will be done.
    Old technology? What? BSX has Taxus Liberte in Europe, but in the U.S. Liberte is out 16 to 19 months. Unless I have missed it I have not seen an announcement of having completed enrollment. JNJ is at least out 24 months. In Cardiology that is a long time! What do you mean when it is completed? It has been completed for a long time. The better question is why JNJ has held up the results. I will re-state my point however, and that is unless Reality shows a major advantage of one over the other, most docs have made up there minds on what they are going to use. I respectfully disagree.

 
BSX
14.84-0.09(-0.60%)Jan 23 4:01 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.